Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Gross Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed Gross Margin for 16 consecutive years, with 51.83% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin rose 377.0% to 51.83% in Q3 2025 year-over-year; TTM through Sep 2025 was 46.2%, a 1001.0% decrease, with the full-year FY2025 number at 48.7%, down 580.0% from a year prior.
  • Gross Margin was 51.83% for Q3 2025 at IGC Pharma, up from 46.95% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 67.86% in Q3 2021 to a low of 30.72% in Q4 2022.
  • A 5-year average of 50.51% and a median of 48.06% in 2024 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: skyrocketed 4706bps in 2021, then crashed -2473bps in 2024.
  • IGC Pharma's Gross Margin stood at 43.66% in 2021, then decreased by -30bps to 30.72% in 2022, then soared by 112bps to 65.2% in 2023, then crashed by -38bps to 40.47% in 2024, then rose by 28bps to 51.83% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Gross Margin are 51.83% (Q3 2025), 46.95% (Q2 2025), and 46.67% (Q1 2025).